The combination of durvalumab and tremelimumab-actl conferred a sustained OS benefit at 4 years among patients with unresectable hepatocellular carcinoma, according to phase 3 trial results from the ...

In this study, researchers evaluated patients who had incomplete cCRT or experienced progression during or within 42 days of receiving cCRT, with an aim of identifying risk factors for these outcomes.

Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo. The Food and Drug Administration (FDA) has approved Tagrisso ® (osimertinib) ...

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU ® (trastuzumab deruxtecan) in combination with pertuzumab for the first-line ...

The FDA approval of nivolumab plus cisplatin and gemcitabine marks the first concurrent immunotherapy-chemotherapy combination for the population. The trial showed the combination significantly ...

Please provide your email address to receive an email when new articles are posted on . Y-90 resin microspheres are the only approved radioembolization therapy for hepatic cellular carcinoma and ...

SAN FRANCISCO -- After more than 20 years of trying, systemic therapy for unresectable liver cancer has improved outcomes with transarterial chemoembolization (TACE), a randomized trial showed.

Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard first-line treatment resulted in better response rates and improved survival for patients with unresectable hepatocellular ...

The Hepzato Kit is the first FDA-approved liver-directed therapy for unresectable metastatic uveal melanoma, showing consistent efficacy across diverse patient subgroups. Patients with lower tumor ...